ISSN: 2960-1959
Publisher
Review Articles

Presentation and Management of Porocarcinoma: A Systematic Review with Meta-Analysis of More Than One Thousand Patients

College of Medicine, University of Sulaimani, Madam Mitterrand Street, Sulaymaniyah, Kurdistan, Iraq
Department of Immunology and Hematology, College of Medicine, Kurdistan University of Medical Science, Sanandaj, Iran
Kscien Organization for Scientific Research (Europe office), Rotterdam, Netherlands
Smart Health Tower, Madam Mitterrand Street, Sulaymaniyah, Kurdistan, Iraq
Department of Biology, College of Education, University of Sulaimani, Sulaymaniyah, Kurdistan, Iraq
Bakhshin Medical Community Halabja, Halabja, Sulaymaniyah, Kurdistan, Iraq
Department of Dermatology, Teaching Center for Treating Skin Diseases, Sulaimani Directorate of Health, Sulaymaniyah, Kurdistan, Iraq
Hiwa Cancer Hospital Centre, Sulaimani Directorate of Health, Sulaymaniyah, Kurdistan, Iraq
Department of Pathology, Sulaimani Surgical Teaching Hospital, Sulaymaniyah, Kurdistan, Iraq
Smart Health Tower, Madam Mitterrand Street, Sulaymaniyah, Kurdistan, Iraq
Department of Biology, College of Education, University of Sulaimani, Madam Mitterrand Street, Sulaymaniyah, Kurdistan, Iraq
Department of Biology, College of Science, University of Sulaimani, Sulaymaniyah, Kurdistan, Iraq
College of Medicine, University of Sulaimani, Madam Mitterrand Street, Sulaymaniyah, Kurdistan, Iraq

Abstract

Introduction

Porocarcinoma is an aggressive cutaneous carcinoma arising from the intraepidermal component of the sweat glands. Given its uncommon nature, only a limited number of studies have addressed this issue. This study summarizes the different presentations and management of the disease.

Methods

The eligible databases were searched to identify English-language studies published up to January 16th, 2024. The inclusion criteria comprised studies that focused on the presentation and management of eccrine porocarcinoma, with a clear statement of the outcomes of the chosen management. The data collected from the studies included the first author's name, country of study, type of study design, patient demography, the clinical presentation of the tumor and its location, histopathological findings, metastasis status, treatment strategy, and the subsequent prognosis.

Results

The initial search yielded 817 papers, with only 22 meeting the inclusion criteria. The studies comprised 1004 patients with a mean age of 78.7 years. In total, 527 (52.5%) of them were male and 461(45.9%) were female. The most commonly affected regions were the head and neck followed by the lower extremities. The most frequent treatment option was surgical excision in 876 (87.3%) patients. Distant metastasis accounted for about 2%, while lymph node involvement, occurred in 36 cases (3.6%). A good prognosis was reported in 57.3% of the cases. Both the age and tumor size had a significant effect on prognosis (p <0.05).

Conclusion
The lesion can develop anywhere on the body, with a survival rate exceeding 50%. Wide-based surgical excision remains the predominant treatment option.

References

  1. Stuart A. Miyamoto K, Yanagi T, Maeda T, Ujiie H. Diagnosis and management of porocarcinoma. Cancers. 2022;14(21):5232. doi:10.3390/cancers14215232.
  2. De Giorgi V, Silvestri F, Savarese I, Venturi F, Scarfì F, Trane L, et al. Porocarcinoma: an epidemiological, clinical, and dermoscopic 20‐year study.2022; 61(9): 1098-1105. doi:10.1111/ijd.16129.
  3. Lloyd MS, El-Muttardi N, Robson A. Eccrine porocarcinoma: a case report and review of the literature. Canadian Journal of Plastic Surgery. 2003;11(3):153-6. doi:10.1177/229255030301100304.
  4. Biondi E, Ranieri G, Nicolò A, Gasparini G. A unique case of eccrine porocarcinoma with pulmonary lymphangitis and pericardial involvement: biological characterization and clinical aggressiveness. Oncology. 2000;59(3):190-5. doi:10.1159/000012160.
  5. Park S, Kim JH. Concurrent presentation of porocarcinoma and basal cell carcinoma arising on a capillary malformation: a case report. Archives of Craniofacial Surgery. 2023;24(5):236. doi:10.7181%2Facfs.2023.00388.
  6. Le HM, Faugeras L, De Moor V, Fervaille C, Vander Borght T, Collette F, et al. Eccrine porocarcinoma: a challenging diagnostic and therapeutic tumoral entity. Case reports in oncology. 2021;14(2):700-5. doi:10.1159/000514984.
  7. Sawaya JL, Khachemoune A. Poroma: a review of eccrine, apocrine, and malignant forms. International Journal of Dermatology. 2014;53(9):1053-61. doi:10.1111/ijd.12448.
  8. Shiohara J, Koga H, Uhara H, Takata M, Saida T. Eccrine porocarcinoma: clinical and pathological studies of 12 cases. The Journal of dermatology. 2007;34(8):516-22. doi:10.1111/j.1346-8138.2007. 00324.x
  9. Luz MD, Ogata DC, Montenegro MF, Biasi LJ, Ribeiro LC. Eccrine porocarcinoma (malignant eccrine poroma): a series of eight challenging cases. Clinics. 2010; 65:739-42. doi:10.1590/S1807-59322010000700014.
  10. Orella JA, Peñalba AV, San Juan CC, Nadal RV, Morrondo JC, Alvarez TT. Eccrine porocarcinoma: report of nine cases. Dermatologic surgery. 1997;23(10):925-8. doi:10.1111/j.1524-4725. 1997.tb00751.x
  11. Mahomed F, Blok J, Grayson W. The squamous variant of eccrine porocarcinoma: a clinicopathological study of 21 cases. Journal of clinical pathology. 2008;61(3):361-5. doi:10.1136/jcp.2007.049213.
  12. Kurashige Y, Minemura T, Nagatani T. Eccrine porocarcinoma: clinical and pathological report of eight cases. Case reports in dermatology. 2013;5(3):259-66. doi:10.1159/000355606.
  13. Gu LH, Ichiki Y, Kitajima Y. Aberrant expression of p16 and RB protein in eccrine porocarcinoma. Journal of cutaneous pathology. 2002;29(8):473-9. doi:10.1034/j.1600-0560.2002. 290805.x
  14. Xu YG, Aylward J, Longley BJ, Hinshaw MA, Snow SN. Eccrine porocarcinoma treated by Mohs micrographic surgery: over 6-year follow-up of 12 cases and literature review. Dermatologic Surgery. 2015;41(6):685-92. doi:10.1097/DSS.0000000000000382.
  15. Zahn J, Chan MP, Wang G, Patel RM, Andea AA, Bresler SC, et al. Altered Rb, p16, and p53 expression is specific for porocarcinoma relative to poroma. Journal of Cutaneous Pathology. 2019;46(9):659-64. doi:10.1111/cup.13480
  16. Yamamoto O, Haratake J, Yokoyama S, Imayama S, Asahi M. A histopathological and ultrastructural study of eccrine porocarcinoma with special reference to its subtypes. Virchows Archiv A. 1992;420: 395-401. doi:10.1007/BF01600510.
  17. Meriläinen AS, Von WILLEBRAND-BÄCKMAN M, Sihto H, Koljonen V. Eccrine Porocarcinoma: Clinical and Histopathological Study of 14 Patients with Special Emphasis on Sentinel Lymph Node Biopsy. Acta Dermato-Venereologica. 2023;103: 11649. doi:10.2340%2Factadv.v103.11649
  18. Kazakov DV, Kutzner H, Spagnolo DV, Kempf W, Zelger B, Mukensnabl P, et al. Sebaceous differentiation in poroid neoplasms: report of 11 cases, including a case of metaplastic carcinoma associated with apocrine poroma (sarcomatoid apocrine porocarcinoma). The American journal of dermatopathology. 2008;30(1): 21-6. doi:10.1097/DAD.0b013e31815f2ae3.
  19. Gómez-Zubiaur A, Medina-Montalvo S, Vélez-Velázquez MD, Polo-Rodríguez I. Eccrine porocarcinoma: patient characteristics, clinical and histopathologic features, and treatment in 7 cases. Actas Dermo-Sifiliográficas (English Edition). 2017 ;108(4):e27-32. doi:10.1016/j.ad.2016.04.024
  20. Villena JP, Ke BN, Ciriaco-Tan CP. Malignant Mystique: Porocarcinoma in Three Adult Filipinos. Acta Medica Philippina. 2020;54(3):327-31. doi:10.47895/amp.v54i3.1681
  21. Shope C, Andrews L, Forcucci J. Comparing Porocarcinoma Outcomes Following Resection by Surgical Management Technique. SKIN The Journal of Cutaneous Medicine. 2023;7(6): 1161-4. doi:10.25251/skin.7.6.13
  22. Yazar SK, Serin M. Results of surgical treatment of patients with malignant eccrine poroma. Şişli Etfal Hastanesi Tip Bülteni. 2019;53(1): 33-6. doi:10.14744/SEMB.2018.10170
  23. Goto K, Takai T, Fukumoto T, Anan T, Kimura T, Ansai SI, et al. CD117 (KIT) is a useful immunohistochemical marker for differentiating porocarcinoma from squamous cell carcinoma. Journal of Cutaneous Pathology. 2016;43(3): 219-26. doi:10.1111/cup.12632
  24. Kervarrec T, Frouin E, Collin C, Tallet A, Tallegas M, Pissaloux D, et al. Distinct regulations driving YAP1 expression loss in poroma, porocarcinoma and RB1‐deficient skin carcinoma. Histopathology. 2023;82(6):885-98. doi:10.1111/his.14874
  25. Puttonen M, Isola J, Ylinen O, Böhling T, Koljonen V, Sihto H. UV-induced local immunosuppression in the tumour microenvironment of eccrine porocarcinoma and poroma. Scientific Reports. 2022;12(1):5529. doi:10.1038/s41598-022-09490-5
  26. Joshy J, van Bodegraven B, Mistry K, Craig P, Rajan N, Vernon S, et al. Epidemiology of porocarcinoma in England 2013-18: a population-based registry study. Clinical and Experimental Dermatology. 2023;48(7):770-77. doi:10.1093/ced/llad122
  27. Riera‐Leal L, Guevara‐Gutiérrez E, Barrientos‐García JG, Madrigal‐Kasem R, Briseño‐Rodríguez G, Tlacuilo‐Parra A. Eccrine porocarcinoma: epidemiologic and histopathologic characteristics. International Journal of Dermatology. 2015;54(5): 580-6. doi:10.1111/ijd.12714
  28. Belin E, Ezzedine K, Stanislas S, Lalanne N, Beylot‐Barry M, Taieb A, Vergier B, Jouary T. Factors in the surgical management of primary eccrine porocarcinoma: prognostic histological factors can guide the surgical procedure. British Journal of Dermatology. 2011;165(5): 985-9. doi:10.1111/j.1365-2133.2011. 10486.x
  29. Kim HJ, Kim A, Moon KC, Seo SH, Kim IH, Kim A, Baek YS. Eccrine porocarcinoma: a multicenter retrospective study with review of the literatures reported in Korea. Annals of Dermatology. 2020;32(3): 223. doi:10.5021/ad.2020.32.3.223
  30. Muhialdeen AS, Ahmed JO, Baba HO, Abdullah IY, Hassan HA, Najar KA, et al: Kscien's List; A New Strategy to Discourage Predatory Journals and Publishers (Second Version). Barw Medical Journal. 2023; 1 (1): 24 26. doi:10.58742/Barw Medical Journal. v1i1.14
  31. Salih AM, Kakamad FH, Baba HO, Salih RQ, Hawbash MR, Mohammed SH, et al. Porocarcinoma; presentation and management, a meta-analysis of 453 cases. Annals of medicine and surgery. 2017;20: 74-9. doi:10.1016/j.amsu.2017.06.027
  32. Mahmood ZH, Mohemed FM, Fatih BN, Qadir AA, Abdalla SH. Cancer publications in one year (2022); a cross-sectional study. Barw Medical Journal. 2023;1(2):18-26. doi:10.58742/bmj.v1i2.30
  33. Fujimura T, Hashimoto A, Furudate S, Kambayashi Y, Haga T, Aiba S. Successful treatment of eccrine porocarcinoma metastasized to a cervical lymph node with CyberKnife radiosurgery. Case Reports in Dermatology. 2014;6(2): 159-63. doi:10.1159/000365348
  34. Robson A, Greene J, Ansari N, Kim B, Seed PT, McKee PH, et al. Eccrine porocarcinoma (malignant eccrine poroma): a clinicopathologic study of 69 cases. The American journal of surgical pathology. 2001;25(6): 710-20. doi:10.1097/00000478-200106000-00002.
  35. Asghar AH, Mahmood H, Faheem M, Rizvi S, Khan KA, Irfan J. Porocarcinoma: a rare sweat gland malignancy. J Coll Physicians Surg Pak. 2009;19(6): 389-90. doi: N/A

Send mail to Author


Send Cancel
Themes by Openjournaltheme.com